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Abstract
Background: Human Immunodeficiency Virus (HIV) persists to be a significant public health issue worldwide. The
current strategy for the treatment of HIV infection, Highly Active Antiretroviral Therapy (HAART), has reduced deaths
from AIDS related disease, but it can be an expensive regime for the underdeveloped and developing countries
where the supply of drugs is scarce and often not well tolerated, especially in persons undergoing long term
treatment. The present therapy also has limitations of development of multidrug resistance, thus there is a need for
the discovery of novel anti-HIV compounds from plants as a potential alternative in combating HIV disease.
Methods: Ten Indian medicinal plants were tested for entry and replication inhibition against laboratory adapted
strains HIV-1IIIB, HIV-1Ada5 and primary isolates HIV-1UG070, HIV-1VB59 in TZM-bl cell lines and primary isolates HIV-
1UG070, HIV-1VB59 in PM1 cell lines. The plant extracts were further evaluated for toxicity in HEC-1A epithelial cell
lines by transwell epithelial model.
Results: The methanolic extracts of Achyranthes aspera, Rosa centifolia and aqueous extract of Ficus benghalensis
inhibited laboratory adapted HIV-1 strains (IC80 3.6–118 μg/ml) and primary isolates (IC80 4.8–156 μg/ml) in TZM-bl
cells. Methanolic extract of Strychnos potatorum, aqueous extract of Ficus infectoria and hydroalcoholic extract of
Annona squamosa inhibited laboratory adapted HIV-1 strains (IC80 4.24–125 μg/ml) and primary isolates (IC80 18–
156 μg/ml) in TZM-bl cells. Methanolic extracts of Achyranthes aspera and Rosa centifolia, (IC801-9 μg/ml) further
significantly inhibited HIV-1 primary isolates in PM1cells. Methanolic extracts of Tridax procumbens, Mallotus
philippinensis, Annona reticulate, aqueous extract of Ficus benghalensis and hydroalcoholic extract of Albizzia lebbeck
did not exhibit anti-HIV activity in all the tested strains. Methanolic extract of Rosa centifolia also demonstrated to
be non-toxic to HEC-1A epithelial cells and maintained epithelial integrity (at 500 μg/ml) when tested in transwell
dual-chamber.
Conclusion: These active methanolic extracts of Achyranthes aspera and Rosa centifolia, could be further subjected
to chemical analysis to investigate the active moiety responsible for the anti-HIV activity. Methanolic extract of Rosa
centifolia was found to be well tolerated maintaining the epithelial integrity of HEC-1A cells in vitro and thus has
potential for investigating it further as candidate microbicide.
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Background
Human Immunodeficiency Virus (HIV) persists to be a
significant public health issue worldwide. In 2018, 37.9
million people are living with HIV globally; out of which
36.2 million are adults and 1.7 million are children less
than 15 years old. There were 1.7 million new infections
and 770,000 people died from AIDS related illness
worldwide [1]. The current strategy for the treatment of
HIV infection is Highly Active Antiretroviral Therapy
(HAART), based on combination of inhibitors of reverse
transcriptase and protease. Although HAART has con-
siderably reduced deaths from AIDS related disease, it
often has side effects and not well tolerated especially in
persons undergoing long term treatment and maintains
the risk of developing multidrug resistance [2]. More-
over, HAART is an expensive regime for underdevel-
oped and developing countries where the drugs are
inaccessible to the HIV infected patients. Thus, there is
a need for the discovery of novel therapeutic strategies,
which identify new anti-HIV compounds from natural
sources particularly from medicinal plants.
Natural sources provide a large reservoir for screening
of anti-HIV agents with novel structure and antiviral
mechanism due to their structural diversity. For the pur-
pose of this study, ten Indian traditional medicinal plants,
Albizzia lebbeck, Tridax procumbens, Achyranthes aspera,
Ficus benghalensis, Mallotus philippinensis, Rosa centifo-
lia, Strychnos potatorum, Annona reticulate, Ficus infec-
toria and Annona squamosa were selected to investigate
their in vitro inhibitory activity against entry inhibition/
replication of HIV-1 as first step towards identification of
potential anti-HIV microbicide. The microbicides provide
protection by directly inactivating HIV or preventing HIV
from attaching, entering or replicating in susceptible tar-
get cells as well as dissemination from target cells present
in semen or the host cells that line the vaginal/rectal wall
[3]. These plants were selected on the basis of detailed pa-
tent survey and scientific articles on the ethnomedicinal
usages of the plant genera directly in HIV/AIDS or for
symptoms/conditions closely associated with this disease
(Table 1).
Plants such as R. centifolia, S. potatorum, F. infectoria, F.
benghalensis and M. philippinensis were selected because
other species of the same genera have exhibited anti-HIV
activity [56–60]. Its traditional use in gonorrhoea and leu-
keorrhea [61] and suppressive effects on sperm motility
[39] further made S. potatorum, a plant of choice for this
study. Fruit pulp of A. squamosa has been reported to in-
hibit HIV replication significantly in H9 lymphocytes [49]
therefore the seeds of A. squamosa which have also shown
spermicidal property, an additional desirable attribute for
a vaginal microbicide [62] was selected for the study. In
addition the leaves of other species A. reticulate were also
selected for assessing the anti-HIV activity.
Taylor et al., [63, 64] reported methanolic extract of T.
procumbens to exhibit in-vitro anti-Herpes Simplex
Virus activity in Vero cells; hence it was selected for
investigating its anti-HIV activity. Anticipating the po-
tential of spermicide-based vaginal contraceptives in the
reproductive health of women such as Nonoxynol (N-9)
and Praneem polyherbal (Azadirachta indica leaves,
Sapindus mukerossi pericarp of fruit and Mentha citrate
oil) [65]; two plant extracts, methanolic leaf extract of A.
aspera that has exhibited safety as well as good anti-
fertility property [66] and methanolic pod extract of A.
lebbeck which has been shown to suppress spermatogen-
esis and alter the structure and activity of the Sertoli and
Leydig cells [4] were considered worthwhile to explore
for anti-HIV activity.
Therefore, under the DBT-ICMR sponsored programme
(HIV/AIDS and Microbicides, Phase I) developed for screen-
ing plant derived HIV microbicidal candidates, we evaluated
these 10 plant extracts against 2 CXCR4 (HIV-1IIIB, HIV-
1UG070) and 2 CCR5 tropic (HIV-1Ada5, HIV-1VB59) HIV-1
strains.
Methods
Plant materials and extraction
10 plant materials were collected from various parts of
India in different seasons. A plant taxonomist at publicly
available herbarium, Botanical Survey of India, Pune,
India, validated scientific names and classification of
these plants. The specimens were also deposited in the
herbarium. Table 2 presents ethno-botanical information
and solvents used for extraction of the selected plants.
The collected plant materials were cleaned, freed of
foreign contaminates and washed with water, first air
dried and then dried in an electric oven at 40 °C. The
dried plant materials were pulverized in an electric
mixer. The plant materials were extracted with various
solvents individually by hot continuous Soxhlet extrac-
tion method for 18–24 h. After extraction, the extract
obtained was filtered through 0.2-μm syringe filter and
then concentrated on a rotary evaporator by distilling off
the solvent under vacuum at 40 °C. The concentrated
extracts was finally lyophilized to obtain free flowing
powder and stored in airtight bottles in the refrigerator
at 4-8 °C. The extractive yields of the individual extracts
are recorded in Table 2. Powder was reconstituted in
DMSO for final concentration of extract 10 mg/ml and
stored at -20 °C until tested for anti-HIV1 activity.
Preliminary phytochemical investigation
Qualitative tests were carried out to ascertain the
presence of various phytochemicals in the plants ex-
tract of the selected plants using the methods de-
scribed by Harbourne [67] (Table 3). It involved the
appropriate addition of chemicals and reagents to the
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concentrated extract of the plant material in a test
tube. The changes in the appearance of the colour, as
the case may be, confirmed the presence of alkaloids,
flavanoids, tannins, steroids and saponins.
Cells, viral strain and culture conditions
TZM-bl (recombinant HeLa cells expressing high levels
CD4 receptor, CXCR4 and CCR5 co-receptors) and
PM1 cells (Clonal derivative of HUT 78) were obtained
from the National Institutes of Health AIDS Research
and Reference Reagent Program (NIH ARRRP). The
HEC-1A (human endometrial adenocarcinoma) cell line
was kindly provided by Dr. R. Fichorova (Associate Pro-
fessor, Brigham and Women’s Hospital, Boston, USA)
and National Institute of Virology, Pune, respectively.
The TZM-bl cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM, Sigma-Aldrich, USA)
and PM1 and HEC-1A cells in RPMI-1640 (Sigma-Al-
drich, USA), supplemented with 10% heat inactivated
fetal bovine serum (FBS, Moregate Biotech, Australia)
and standard antibiotic-antimycotic cocktail.
Table 1 Ethnomedicinal usages of selected plant materials
Sr No Botanical name Common name Family Conventional use and published reports
1 Albizzia lebbeck Shirisha Mimosaceae Bark: Anti-oxidant, anti-fertility, anti- microbial activity
Seeds: Anti-inflammatory activity [4, 5].
2 Tridax procumbens Ghamra Asteraceae Whole plant: Anti-microbial
Flowers, Leaves: Anti septic, insecticidal, parasiticidal,
anti-Cancer Activity
Aerial parts: Hepatoprotective
Leaves: Hypotensive, anti- diabetic,
immunomodulating activity [6–12].
3 Achyranthes aspera Apaamaarga Amaranthaceae Whole plant: Nephroprotective, hypolepidemic activity.
Roots: anti-oxidant, spermicidal, activity
Leaves: anti-oxidant, anti-fertility, anti-depressant,
anti-cancer, anti- microbial activity
Aerial parts: Hepatoprotective activity
Seeds: Anti- microbial activity [13–22].
4 Ficus benghalensis Vad Moraceae Whole plant: anthelmentic, anti-bacterial activity.
Bark: Anti-inflammatory, anti-bacterial activity.
Aerial roots: anti-oxidant, anti-diabetic,
immunomodulatory activity [23–27].
5 Ficus infectoria Pilkhan Bark and Leaves: anti-oxidant,
anti-hyperlipidemic, hypoglycemic activity [28].
6 Mallotus philippinensis Kamala Euphorbiaceae Seeds: Anti-fertility activity.
Stembark: anti-oxidant, anti-tumor activity,
anti- bacterial.
Fruits: anti-inflammatory, immunoregulatory,
anti-proliferative activity.
Leaves: Hepatoprotective activity
Roots: Anti-leukaemic activity [29–36].
7 Rosa centifolia Gulab Rosaceae Leaves: treating wounds, ophthalmia, hepatopathy,
hemorrhoids and anti-microbial,
Flowers: cardio tonic, anti-inflammatory, anti-asthmatic,
anti-bronchitic, anti-diarrheal, dysmenorrheal, urinary
tract infections, anti-tussive activity [37, 38].
8 Strychnos potatorum Nirmali Loganiaceae Plant: Anti-diabetic, anti- microbial activity
Seeds: Contraceptive, diuretic, anti-inflammatory,
hepatoprotective, antioxidant, antiarthritic
activity [39–45].
9 Annona reticulate Ramphal Annonaceae Leaves: Anti-oxidant, anti- inflammatory, anti-helmentic
activity.
Seeds: Anti-cancer [46–48].
10 Annona squamosa Sitafal Bark: Anti-malarial activity
Seeds: Anti-tumor activity
Twigs: Anti-ulcer activity
Leaves: anti- oxidant,hepatoprotective, anti- bacterial
activity
Fruit pulp: Anti-HIV activity [49–55].
Legend: Details of plants selected and their reported conventional use
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The laboratory adapted HIV-1 strains [HIV-1IIIB (X4,
subtype B), HIV-1Ada5 (R5, subtype B)] and the primary
isolate HIV-1UG070 (X4, Subtype D) were procured from
National Institutes of Health-AIDS Research and Reference
Reagent Program, while the Indian isolate HIV-1VB59 (R5,
subtype C) was obtained from the National AIDS Research
Institute (NARI), Pune. Phytohemagglutinin-P (5 μg/ml,
Sigma Aldrich, USA) activated peripheral blood mono-
nuclear cells (PBMC) derived from healthy donors were
used for the growth of all the viral strains. HIV-1 p24 anti-
gen detection kit (Vironostika HIV-1 Antigen, Netherlands)
was used to determine the virus production in cell cul-
ture supernatants. Samples of viral culture supernatants
free form cells were obtained by centrifugation and fur-
ther filtered and finally stored at -70oC for further use.
Spearman Karber formula was used to ascertain the
50% tissue culture infectivity dose (TCID50) of each
virus stock in both TZM-bl and PM1 cells [68].
Anti HIV1 assays
Determination of cytotoxicity in the uninfected TZM-bl and
PM1 cell lines
The cytotoxicity of the extracts was determined in un-
infected TZM-bl cells using colorimetric assay that
measures the reduction of a yellow 3-(4,5-dimethythia-
zol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) by
mitochondrial succinate dehydrogenase (Sigma Aldrich,
USA) [69]. Briefly, two-fold dilutions of the extracts
were prepared, added to 96 well plates pre-seeded with
TZM-bl cells (10,000 cells/well) in quadruplicate and
incubated for 48 h at 37 °C. The MTT (20 μl, 5 mg/ml)
solution was added and the plates were incubated
Table 3 Phytochemical screening of selected plant extracts
Sr. No. Plant Extracts Steriods Saponins Flavanoids Alkaloids Tannins/ Phenolic Compounds
1 A. lebbeck +++ + + ++++ ++
2 T. procumbens – – + – –
3 A. aspera +++ + + ++++ ++++
4 F. benghalensis +++ + + ++++ +++
5 M. philippinensis – + + ++++ ++
6 R. centifolia – + + ++++ ++
7 S. potaotorum +++ + – ++++ ++
8 A. reticulate +++ – + ++++ +++
9 F. infectoria ++ + ++ ++++ ++++
10 A. squamosa – + + ++++ ++
Legend: presence or absence of phytochemical components in plant extracts by different methods
-: Absent, ++++: Present in large proportion, +++: Present in good proportion, ++: Present in moderate proportion, +: Present in low proportion
Tests for Steroid: 1. Salkowski Reaction 2. Liebermann- Burchard Reaction 3. Liebermann’s Reaction
Tests for Saponins: 1. Foam Test
Tests for Flavanoids: 1. Shinoda Test 2. Lead acetate Test
Test for Alkaloids: 1. Dragendorff’s Test 2. Mayer’s Test 3. Hager’s Test 4. Wagner’s Test
Test for Tannins and Phenolic compounds: 1. 5% Ferric Chloride 2. Dilute Iodine Solution 3. Lead acetate solution 4. Dilute Potassium permanganate solution
Table 2 Procurement, authentication and solvents used for extraction of plant material
Sr. No. Plant Name Part of plant Authentication No. Solvent for extraction % yield (± SD)
1 Albizzia lebbeck Whole pods RR 3794 Hydroalcohol 17.20 (±0.32)
2 Tridax procumbens Aerial parts KK1 Methanol 7.2 (±1.32)
3 Achyranthes aspera Aerial parts PADAAP1 Methanol 10.74 (±0.02)
4 Ficus benghalensis Leaves PADFB1 Water 7.56 (±0.52)
5 Mallotus philippinensis Leaves MPADP12 Methanol 5.72 (± 0.09)
6 Rosa centifolia Leaves ROAP1 Methanol 9.46 (± 0.56)
7 Strychnos potatorum Seeds SPAP2 Methanol 15.00 (±0.43)
8 Annona reticulata Leaves APAR1 Methanol 7.89 (±0.07)
9 Ficus infectoria Leaves APF1 Water 19.08 (±0.02)
10 Annona squamosa Seeds SS1/ 2008 Hydroalcohol 10.87 (±0.15)
Legend: Procurement, authentication no. & extraction details of the plants parts used for the study
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further for 4 h. The supernatant was removed, 200 μl of
DMSO was added, the plates were incubated for 1 h
and the absorbance was read at 550 nm and 630 nm.
The percent viability was calculated by comparing cell
viability in the absence of extract using following for-
mula and the results were expressed as CC50 (50% cyto-
toxic concentration).
%Cell Viability ¼ OD test extract=Average OD control½   100
The cytotoxicity in uninfected PM1 cells of all the ex-
tracts was determined in a similar manner by using a simi-
lar dilution scheme and procedure as mentioned above for
TZM-bl cells. The cell viability was determined by the try-
pan blue dye exclusion assay (Sigma Aldrich, USA) and
the results were expressed as CC50 [70].
Preliminary screening for anti-HIV1 activity against
laboratory adapted strains in TZM-bl cell lines
The anti-HIV1 activity was tested against Cell-free (CF)
and Cell-associated (CA) X4 tropic (HIV-1 IIIB) and R5
tropic (HIV-1Ada5) laboratory adapted strains in TZM-
b1 cell lines.
In cell free assay, the viral stocks (400 TCID50) were
pre-treated in duplicate with sub toxic concentrations
of the extracts/fractions for 1 h, at 37 °C prior to
addition onto the TZM-bl cells (10,000 cells/well).
While in cell-associated assay, the cells (10,000 cells/
well) were pre-infected with the viral stocks (400
TCID50) for 2 h at 37 °C before exposure to the ex-
tracts/fractions [71]. After 48 h, the supernatant was
collected and luciferase activity was determined using
Britelite plus (Perkin Elmer, USA). Dextran Sulphate
(Sigma Aldrich, USA) and Azidothymidine (AZT, CIPLA,
India) were used as positive controls for cell free and cell
associated assays respectively. The results were expressed
as IC50 (50% inhibitory concentration), IC80 (80% inhibitory
concentration) and Therapeutic Index (TI=CC50/IC50).
Confirmation of anti-HIV1 activity against primary isolates
in TZM-bl and PM1 cell lines
The anti-HIV1 activity was tested against Cell-free (CF)
and Cell-associated (CA) X4 tropic (HIV-1 UG070) and
R5 tropic (HIV-1 VB59) primary isolates in TZM-b1 and
PM1 cell lines.
The procedure for anti-HIV1 activity against primary
isolates in TZM-bl cell lines followed was same as men-
tioned above for anti-HIV1 activity against laboratory
adapted strains. The results were expressed as percent-
age inhibition calculated using following equation
The results were expressed as IC80 (80% inhibitory
concentration).
The anti-HIV activity against primary isolates was also
evaluated in PM1 cell lines using 24-well plate (Corning,
USA). In the cell free assay, 20 TCID50 the viral stock
(HIV-1UG070 and HIV-1VB59) was pre-treated with sub
toxic concentrations of the extracts/fractions, before
addition onto the cells (5x104cells/well). Whereas, in the
cell associated assay, the PM1 cells (5x104cells/well)
were pre-infected with 20 TCID50 of the viral stock and
then exposed to the extracts/fractions [72]. The virus
growth was monitored by Vironostika®p24 antigen
ELISA (Biomerieux, France). Dextran sulphate and AZT
were used as positive controls for cell free and cell asso-
ciated assays respectively. The percent inhibition was
calculated by comparing activity in absence of the ex-
tracts/fractions/control drug using the formula men-
tioned above and the results were expressed as IC80.
Toxicity testing using Transwell epithelial model
Cytotoxicity assay
The toxicity of selected plant extract was determined in
HEC-1A using similar protocol as described for TZM-bl
cells, only with a difference of the read out system, i.e. LDH
cytotoxicity detection kit (Roche Diagnostics, Germany).
Determination of epithelial integrity in Transwell dual-
chamber system
The epithelial integrity was determined as described by
Gali et al., [73]. Briefly, HEC-1A cells (1 × 105/100 μl) were
cultured for 7 days on the apical chamber of a Laminin
coated dual-chamber Transwell® system (growth area:
0.3cm2, pore size: 3.0 μm) (Corning Costar Corp, USA).
After 7 days incubation, two-fold serial dilutions of test
preparations (100 μl) were added on to the HEC-1A cells
and incubated for 24 h (37 °C, 5% CO2). The test prepara-
tions were removed and 100 μl of a 1/20 dilution of
yellow-green fluorescent microspheres (FluoSpheres®
sulphate microspheres, Molecular Probes Europe NV,
Netherlands) were added in the apical chamber. After
24 h, 100 μl of medium was harvested from the basal
chamber and the fluorescence was measured using a
fluorometer (Perkin Elmer, USA). Untreated HEC-1A
cells and 1% Nonoxynol-9 were used as controls for
measuring percent transmission.
Results
Preliminary phytochemical investigation
The preliminary phytochemical evaluation of plant ex-
tracts for the presence of steriods, flavanoids, alkaloids,
%Inhibition ¼ 1−½ðluminescence in presence of the test extract or fraction
luminescence of uninfected control cells=luminescence of cells infected with virus
luminescence of uninfected control cellsÞ  100
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saponins, tannins and phenolic acids was done for 10
plants extracts from 8 different families. Steroids were
not present in T. procumbens, M. philippinensis, R. centi-
folia and A. squamosa extracts and the Saponins in T.
procumbens and A. reticulate extract. Only flavanoids
was present in T. procumbens extract while it was not
present in S. potaotorum extract (Table 3).
Determination of cytotoxicity in TZM-bl and PM1 cell lines
Six methanolic extracts, two aqueous extracts and
two hydroalcoholic extracts of 10 medicinal plants
were examined for their ability to inhibit HIV-1 entry
and replication. The in vitro toxicity of these extracts
to TZM-bl cells was investigated by MTT assay.
Methanolic extracts of, A. aspera, hydroalcoholic ex-
tract of A. squamosa and water extract of F. bengha-
lensis tested were relatively non-toxic to TZM-bl cells
at a CC50 value between 51 and 72 μg/ml. The CC50
values of other extracts such as methanolic extract of,
R. centifolia, S. potatorum and aqueous extract of F.
infectoria were found to be comparatively higher ran-
ging between 118 and 147 μg/ml. However, methano-
lic extract of A. reticulate was found to be toxic at a
very low concentration (CC50 = 11 μg/ml) as com-
pared to the other extracts (Tables 4 and 5).
Cytotoxicity of plant extracts, A. aspera, F. benghalensis,
R. centifolia, S. potatorum, F. infectoria and A. squamosa
showing activity in preliminary anti-HIV-1 assay was carried
out in PM1 cells using trypan blue dye exclusion assay. The
50% cytotoxicity was observed at a concentrations ranging
from 2.9–46 μg/ml. Aqueous extract of F. benghalensis was
toxic at a very low concentration as compared to other ex-
tracts (Table 5).
Preliminary screening for anti-HIV1 activity against
laboratory adapted strains in TZM-bl cell lines
Plant extracts of A. aspera, F. benghalensis, R. centifolia,
S. potatorum, F. infectoria and A. squamosa showed in-
hibition of HIV-1IIIB and HIV-1Ada5 laboratory adapted
strains in both cell free and cell associated assays. Aque-
ous extract of F. infectoria revealed significant activity
against the laboratory adapted strains with estimated
IC80 in the range of 4.24–125 μg/ml giving TI of 189, 49
and 27 in cell free HIV-1IIIB, HIV-1Ada5 and cell associ-
ated HIV-1IIIB respectively. This was followed by metha-
nolic extract of A. aspera which showed activity with
preliminary IC80 in the range of 18–35 μg/ml giving TI
of 14, 35 and 13 in cell free HIV-1IIIB, HIV-1Ada5 and
cell associated HIV-1IIIB respectively. Aqueous extract of
F. benghalensis exhibited activity in both laboratory
adapted strains with estimated IC80 in the range of 18–
35 μg/ml giving TI between12–32. Methanolic extract of
S. potatorum showed activity with preliminary IC80 in
the range of 29.17–79.35 μg/ml giving estimated TI of
24 in cell free HIV-1Ada5 strain. Methanolic extract of R.
centifolia and hydroalcoholic extract of A. squamosa
displayed very low activity (estimated TI in the range of
1–6). Hydroalcoholic extract of A. lebbeck, methanolic
extract of T. procumbens, M. philippinensis and A. re-
ticulate did not demonstrate any activity against cell free
and cell-associated laboratory adapted HIV-1 strains.
Confirmation of anti-HIV activity against primary isolates
in TZM-bl and PM1 cell lines
The plant extracts showing activity in preliminary
screening against laboratory adapted strains were further
screened both cell free and cell associated assays against
primary isolates HIV-1UG070 and HIV-1VB59 in TZM-b1
Table 4 Inhibitory concentrations and therapeutic index of plant extracts against Laboratory adapted HIV-1IIIB and HIV-1Ada5 strains
in TZM-bl cell lines
Sr.
No.
Plant Extract CC50
(μg/
ml)
IC50 IC80 Therapeutic Index
CF CA CF CA CF CA
IIIB Ada5 IIIB Ada5 IIIB Ada5 IIIB Ada5 IIIB Ada5 IIIB Ada5
1 A. lebbeck 203 No activity
2 T. procumbens 62 No activity
3 A. aspera 69 8.3 2.3 4.1 28.4 18 21 26 35 14 35 13 3
4 F. benghalensis 72 6 6 5.2 2.25 9.6 9.6 8.32 3.6 12 12 14 32
5 M. philippinensis 71 No activity
6 R. centifolia 132 13.6 24.8 51.9 75.4 30.4 45.2 96.1 118 5 6 1 1
7 S. potatorum 124 4.97 3.65 18.51 17.67 29.17 35.89 79.35 78.43 10 24 8 7
8 A. reticulata 11 No activity
9 F. infectoria 147 1.18 2.97 4.97 87.38 4.24 8.6 52.49 > 125 189 49 27 2
10 A. squamosa 51 No activity 23 11.3 No activity 27 20 2 4 2 3
CC50−50% cytotoxic concentration, IC50–50% inhibitory concentration
IC80−80% inhibitory concentration, CF- Cell Free, CA- Cell Associated
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and PM1 cell lines for confirmation of their anti-HIV1
activity.
In TZM-b1 cell lines methanolic extract of A. aspera
and hydroalcoholic extract of A. squamosa exhibited a
very good activity with lowest estimated IC80 of 4.8–
53 μg/ml and 25–27 μg/ml respectively against primary
isolates of HIV-1 strains. This was followed by aqueous
extract of F. infectoria, methanolic extract of S. pota-
torum and R. centifolia and aqueous extract of F. ben-
ghalensis with preliminary IC80 in the range of 18–
73 μg/ml, < 31.25–105 μg/ml, 17- > 125 μg/ml, and < 78-
< 156 μg/ml respectively (Table 5).
In PM1 cell lines, methanolic extract of A. aspera and
R. centifolia showed activity with estimated IC80 ranging
1–9 μg/ml. Aqueous extract of F. benghalensis exhibited
activity at preliminary IC80 of 2.9–3.5 μg/ml in cell free
assay. Methanolic extract of S. potatorum exhibited ac-
tivity at IC80 of 6–29 μg/ml except for HIV-1VB59 cell
free assay. The hydroalcoholic extract of A. squamosa
showed very good activity at lower concentration 0.8 μg/
ml in cell associated assay. Aqueous extract of F. infec-
toria showed activity in cell free assay at a concentration
ranging 2–29 μg/ml (Table 5). The representative dose
response bar graphs for A. aspera and R. centifolia, in
cell free and cell associated assays for TZMb1 and PM1
are given in Additional file 1: (Figures S1 to S5).
Toxicity testing using Transwell epithelial model
Amongst the three extracts which showed highest activity,
methanolic extract of R. centifolia exhibited least toxicity
both inTZM-b1 and PM1 cell lines, therefore it was fur-
ther tested for in vitro activity against HEC-1A cells and
demonstrated minimal cytotoxicity with CC50 of 1443 μg/
ml. Epithelial integrity of HEC-1A in Transwell dual-
chamber system was maintained with only 1% relative
fluorescence (percent of positive control) detected after
treatment with 500 μg/ml of methanolic extract of R. cen-
tifolia. At higher concentration of 1000 μg/ml integrity
was affected with 24% leaked fluorescence relative to posi-
tive control (Fig. 1).
Discussion
Natural products continue to be major sources of in-
novative therapeutic agents for treatment of infectious
diseases, and their exploration has been one of the most
successful strategies for the discovery of medicines. The
development of new microbicides as preventive inter-
ventions is a promising area in AIDS research [3]. They
could be valuable addition in prevention of sexual
transmission of HIV-1 and could be an important way
to reduce the number of cases of HIV infection globally
[74, 75]. Currently available anti-HIV drugs are chem-
ically synthesized and are often limited by side effects
and emergence of drug resistance [76].
In order to find such potential anti-HIV agents from
natural sources, ten traditional medicinal plants from
India were studied for their inhibitory effects against la-
boratory adapted strains HIV-1 IIIB, HIV-1Ada5 and
primary isolates HIV-1UGO70, HIV-1VB59 in TZM-b1
and primary isolates HIV-1UGO70, HIV-1VB59 in PM1
cell lines. HIV viruses can spread in the body via either a
cell-free (virus floating free in plasma) mode or a cell
associated (virus particles that remain attached to or
within the host cell after replication) mode involving dir-
ect cell-cell contact. Hence all the selected plant extracts
were evaluated to depict their mechanism of action,
whether they will act as an entry inhibitor or at the HIV
replication stage [77].
Table 5 Inhibitory concentrations of plant extracts against Primary isolates HIV-1UG070 and HIV-1VB59 in TZM-bl and PM1 cell lines
Extracts/ Fractions/
Controls
TZM-bl assay PM-1 assay
CC50
(μg/
ml)
IC80(μg/ml) CC50
(μg/
ml)
IC80 (μg/ml)
CF
HIV-1
CA
HIV-1
CF
HIV-1
CA
HIV-1
UG
070
VB
59
UG
070
VB
59
UG
070
VB
59
UG
070
VB
59
A. aspera 69 4.8 < 19.53 26 53 10.7 2.6 8.4 1 1.6
F. benghalensis 72 < 78 < 156 < 156 < 78 2.9 3.5 2.9 NA NA
R. centifolia 132 17 33.5 60.5 > 125 20 3.6 6.8 2.2 9
S. potatorum 124 < 31.25 80 60 105 46 29 NA 6 8.3
F. infectoria 147 18 22 42 73 28 2 29 NA NA
A. squamosa 51 27 27 25 26 15.12 NA NA 0.8 0.8
Control DS 5553 6.43 4.5 – – 4978 9.18 16.54 – –
AZT 782 – – 8.01 18.70 998.5 – – 8244.35 12,079.33
CC50 50% cytotoxic concentration, IC80 80% inhibitory concentration, DS Dextran Sulphate, AZT Azidothymidine, CF Cell Free, CA Cell Associated
Legend: The plant extracts showing 80% inhibition of HIV-1 primary isolates (UG070 & VB59) in TZM-bl cell line by cell free and cell associated assay with positive
controls dextran sulphate and azidothymidine respectively
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The selected plant extracts were subjected to high
throughput (cost-effective, quick and reproducible)
TZM-bl assay model which is useful for preliminary
screening allowing screening of large number of prod-
ucts against HIV [70, 78]. The results presented here
indicate that the methanolic extracts of aerial parts of A.
aspera, leaves of R. centifolia and seeds of S. potatorum
and aqueous extract of leaves of F. benghalensis and F.
infectoria possess anti-HIV properties of therapeutic
interest inhibiting HIV-1 virus at an estimated TI of 3–
35, 1–6, 7–24,12–32, and 2–189 respectively against
laboratory adapted strains and at a very low preliminary
IC80 ranging from 4.8–26, 17–125, 31–105, 78–156 and
18–73 μg/ml respectively against primary isolates using
TZM-b1 assay.
The lead extracts were also confirmed for anti-HIV
activity in PM1 cell line which supports persistent
HIV-1 infection [72]. The PM1 cell line have been re-
ported to be comparable to peripheral blood mono-
nuclear cells (PBMCs) for culturing of any of the
HIV-1 strains and subtypes and thus provide a valu-
able research tool for studying new anti-HIV therap-
ies [79]. This cell line has been previously used for
studying the anti-HIV1 properties of the polyherbal
cream Basant [80]. Hence PM-1 was used for
confirming the anti-HIV activity of the methanolic
extracts of aerial parts of A. aspera and leaves of R.
centifolia which showed anti-HIV activity (IC80) ran-
ging between 1 and 8.4 and 2.2–6.8 μg/ml respect-
ively. These extracts may potentially inhibit the entry
and also inhibit HIV-1 replication if the virus enters
the vaginal cells. However further work on more rep-
licates and wider concentration range studies are re-
quired for confirmation. Future studies on PBMCs for
qualifying the results should also be considered.
Our earlier work has shown that methanolic extract of
R. centifolia has also shown activity against four strains
of N. gonorrhoeae [81]. It substantially lacks cytotoxicity
even at high concentrations (CC50 greater than 1 mg/ml)
when tested in vitro on HEC-1A cell line (endometrial
origin) and maintained its epithelial integrity when stud-
ied in Transwell model at concentrations up to 500 μg/
ml thus showing potential for investigating it further as
candidate anti-HIV microbicide.
As per the literature these extracts have not been fur-
ther analyzed chemically, although the active compo-
nents such as oleanolic acid and pomolic acid isolated
from Rosa wodsii leaves the other species of Rosa, have
been reported to inhibit HIV replication in acutely in-
fected H9 cell growth at IC50 of 40 μg/ml [56, 57]. The
literature indicates the phytosteroids, polyphenols and
saponins present in the methanolic leaf extract of A.
aspera are responsible for its anti-fertility effect [66] and
methanolic root extract possess anti-herpes virus activity
at EC50 of 64.4 μg/ml for HSV-1 and 72.8 μg/ml for
HSV-2 [82]
The other selected medicinal plants extract showed
anti-HIV activity against at least any one of the assay
model except for hydroalcoholic extract of whole pods
of A. lebbeck, methanolic extract of aerial parts of T. pro-
cumbens, methanolic extract of leaves of M. philippine-
nis and methanolic extract of leaves of A. reticulate, they
were incapable of showing anti-HIV1 activity against cell
free and cell associated HIV-1IIIB, HIV-1Ada5 laboratory
adapted strains and HIV-1UG070, HIV-1VB59 primary
isolates in TZM-b1 and PM1 cell lines. It’s worth men-
tioning that these plants were selected on basis of their
sub species showing activity against other strains and
primary isolates of HIV and the same species having
contraceptive and activity related to this infectious
Fig. 1 Plot of Relative Fluroscence (%) Vs Concentration (μg/ml) determining epithelial integrity of R. centifolia by measuring permeability to
FluoSpheres using the Dual-Transwell Epithelial Model
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disease. The inactivity of these plants against our test
strains and primary isolates of HIV does not prove that
they do not possess anti-HIV1 activity. These plants can
be taken further for the activity against other strains and
primary isolates of HIV virus using other anti-HIV
assays.
Some plants extract such as F. benghalensis, S. pota-
torum and F. infectoria showed moderate to mild
anti–HIV1 activity. These plants extracts had variable
activities across the assays presented in this study
where the extract exhibited inhibition of one strain of
the primary isolates in one assay but did not inhibit
the same primary isolates in another assay model.
Aqueous extract of leaves of F. benghalensis showed
anti-HIV1 activity against all HIV-1 laboratory adapted
strains and primary isolates using TZM-b1 assay (TI: 12–
32, IC80: 78–156 μg/ml) but did not inhibit cell associated
primary isolates in PM1 assay. Methanolic extract of seeds
of S. potatorum showed anti-HIV1 activity against all
HIV-1 laboratory adapted strains and primary isolates
using TZM-b1 assay (TI: 7–24, IC80: 31.25–105 μg/ml)
but was not capable of inhibiting cell free primary isolate
HIV-1VB59 in PM1 assay. Aqueous extract of leaves of F.
infectoria showed anti-HIV1 activity against all HIV-1 la-
boratory adapted strains and primary isolates using TZM-
b1 assay (TI: 2–189, IC80: 18–73 μg/ml) but did not inhibit
cell associated primary isolates in PM1 assay. Hence these
extracts may not altogether be classified as extracts not
having anti-HIV1 inhibitory potential.
Hydroalcoholic extract of seeds of A. squamosa exhib-
ited activity against all HIV-1 laboratory adapted strains
and primary isolates using TZM-b1 assay (TI: 2–4, IC80:
26–27 μg/ml) but was not capable of inhibiting cell free
primary isolates in PM1 assay. This plant extract has a
some potential to be explored further and may be used
supplementary as a replication inhibitor.
Conclusion
To conclude the study, out of 10 plants screened for
anti-HIV activity using TZM-b1 and PM1 assays, metha-
nolic extracts of aerial parts of A. aspera and leaves of R.
centifolia has prospective anti-HIV1 potential as an entry
and replication inhibitors. Hence these experimental
moieties may have favourable implications on the pre-
vention or management of HIV/AIDS. Additionally
methanolic extract of leaves of R. centifolia have shown
good safety and maintained the epithelial integrity on
HEC-1A cells. Plant extracts are complex mixtures of
many compounds. Some compounds may mask the anti-
HIV1 potential of plant extract due to their cytotoxicity.
Therefore our next step would be isolating the phyto-
constituents and increasing the chances to find active
anti HIV1 compounds with low cytotoxicity.
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